The Recall Desk
HighFDA (Drugs)·D-0161-2025·Announced 2025-01-01

Duloxetine 30mg Capsules Recalled Due to Nitrosamine Impurity

Breckenridge Pharmaceutical is recalling 163,883 bottles of Duloxetine 30mg capsules nationwide due to N-nitroso-duloxetine impurity above FDA-recommended limits.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: FDA Class II recall of a prescription drug containing N-nitroso-duloxetine impurity above FDA-recommended limits. N-nitroso compounds are potentially genotoxic, constituting a risk-of-harm situation where injury has not yet been reported, meeting the rubric criterion for High severity.

Plain-English summary

Breckenridge Pharmaceutical, Inc. is recalling Duloxetine Hydrochloride 30mg delayed-release capsules distributed nationwide in the United States. The recall affects 163,883 bottles (NDC 51991-747-90, 90-count bottles) manufactured by Towa Pharmaceutical Europe in Spain. The affected lot number is 222205C with an expiration date of November 2025.

The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations identified during manufacturing. Specifically, N-nitroso-duloxetine impurity was detected above the FDA-recommended interim limit. N-nitroso compounds are known to be potentially genotoxic.

The recalled product

Product
DULOXETINE (DULOXETINE HYDROCHLORIDE)
Brand
DULOXETINE
Manufacturer
Breckenridge Pharmaceutical, Inc
Category
Drug
Hazard
  • nitrosamine

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot # 222205C
  • exp. date 11/2025

Distribution

Distributed nationwide across the United States.